Business Context and Reporting Period
The filing is Capstone Therapeutics Corp.’s unaudited Form 10-Q for the three months ended March 31, 2016. The provided metadata identifies Capstone Holding Corp.; the filing itself identifies the registrant as Capstone Therapeutics Corp.
The company is a biotechnology business with no revenue-producing operations since the 2003 sale of its Bone Device Business. Its primary current activity is development of AEM-28 and analogs, including AEM-28-14, through its 64%-owned LipimetiX Development, Inc. joint venture. The company operates under a substantially virtual model.
Financial Performance and Position
| Metric | Q1 2016 | Q1 2015 or prior period |
|---|---|---|
| Revenue | None reported | None reported |
| General and administrative expense | $225,000 | $472,000 |
| Research and development expense | $157,000 | $350,000 |
| Total operating expenses | $382,000 | $822,000 |
| Interest and other expense, net | $11,000 | $56,000 |
| Net loss attributable to Capstone stockholders | $379,000 | $716,000 |
| Basic and diluted loss per share | $0.01 | $0.02 |
| Cash and cash equivalents at period end | $718,000 | $1.540 million at March 31, 2015 |
| Cash used in operating activities | $293,000 | $624,000 |
Total assets were $1.413 million at March 31, 2016, versus $1.767 million at December 31, 2015. Current assets were $943,000 and current liabilities were $266,000. The company also had $1.000 million of convertible promissory notes payable, bearing interest at 5% and secured by substantially all company assets.
At March 31, 2016, the company had $1.529 million of outstanding advances to the joint venture under a revolving loan agreement. The advances were subject to a stated net limit of $1.5 million and were due December 31, 2016 under the agreement.
There were no investing or financing cash flows during the quarter. Accumulated deficit was $189.335 million, and stockholders’ equity was $147,000.
Material Changes Versus the Prior Comparable Period
- Total operating expenses declined 54% year over year, primarily due to lower professional fees, insurance costs, and reduced development activity.
- Research and development expense decreased 55%, reflecting a significant reduction in AEM-28 and analog development while the company seeks funding.
- General and administrative expense decreased 52%, partly because the company did not engage an independent public accountant to audit the 2015 annual financial statements or review this Form 10-Q.
- Net loss decreased 47% from $716,000 to $379,000. The MD&A text refers to the 2015 comparative loss as $0.07 million, which conflicts with the financial statements’ reported $716,000 value.
- Cash declined from $1.011 million at December 31, 2015 to $718,000 at March 31, 2016, a $293,000 decrease corresponding to operating cash use.
- On March 31, 2016, the company converted 1.5 million shares of joint venture preferred stock into 120,000 common shares, increasing its joint venture ownership from 60% to 64%.
- The lenders declined in January 2016 to extend their exclusive period or proceed with a proposed additional investment of $7.5 million to $10 million.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management states that the company and its joint venture do not have sufficient funding for additional material development activities or continued operations beyond limited projects currently under way. The company is exploring strategic transactions, fundraising, partnering, and licensing arrangements. No quantitative revenue or earnings guidance was provided.
Management states that additional capital will be required to continue operations and develop AEM-28, AEM-28-14, and other analogs. The company may pursue debt or equity offerings, joint development arrangements, sales of development rights, or licensing transactions, but such funding may be unavailable or materially dilutive.
The financial statements assume continuing operations and disclose substantial doubt about the company’s ability to continue as a going concern. Management indicates that failure to obtain funding within the next 12 months could impair operations and development activities.
- The company did not engage an independent public accountant to audit its December 31, 2015 financial statements or review this Form 10-Q, as required by applicable SEC rules and OTCQB requirements. The company cannot predict potential SEC or OTCQB consequences, including possible effects on trading.
- The $1.0 million convertible notes are due April 30, 2017 if not converted. A qualified equity financing of at least $5.0 million would trigger automatic conversion; other conversion rights and price limits apply.
- If the joint venture or company cannot obtain funding and the joint venture fails as a going concern, the company could incur an additional loss of $667,000 relating to losses allocated to noncontrolling interests.
- The company faces biotechnology development risks, including unfavorable preclinical or clinical results, regulatory delays or denials, competition, intellectual-property impairment, and inability to obtain partners or financing.
- Australian refundable research and development tax credits totaled AUD$208,000, stated as approximately $159,000 in U.S. dollars, and were included in other current assets.
- No legal proceedings were reported as material; the filing states “None” under Legal Proceedings.
Important Facts for Investors to Verify
- Confirm the registrant’s identity and any relationship between Capstone Therapeutics Corp. and the company name supplied in the request.
- Assess the going-concern uncertainty against cash of $718,000, quarterly operating cash burn of $293,000, the $1.0 million note maturity, and the $1.529 million joint venture advances.
- Review the terms, conversion mechanics, security interests, and potential dilution associated with the convertible promissory notes.
- Verify the consequences of the missing independent audit and quarterly review for SEC compliance, OTCQB eligibility, and trading liquidity.
- Evaluate whether additional financing, licensing, partnering, or strategic transactions were subsequently obtained and on what terms.
- Confirm the development status, regulatory pathway, patent position, and funding requirements for AEM-28-14 and related candidates.
- Reconcile the MD&A’s conflicting reference to the 2015 net loss of $0.07 million with the financial statements’ $716,000 figure.